Adaptive Biotechnologies Corporation announced the Company's Chief Commercial Officer of the MRD business, Nitin Sood, resigned to pursue a new opportunity. There are no disagreements or performance matters related to Mr. Sood's decision. His employment with the Company will end on or about August 15, 2023, and his position will not be replaced.

Susan Bobulsky, who has led the clinical business for the past five years, will assume additional responsibilities and report directly to the Company's Chief Executive Officer, Chad Robins.